Anatomic Stage IIIA Breast Cancer AJCC v8 Completed Phase 2 Trials for Mirvetuximab (DB16235)

IndicationStatusPhase
DBCOND0109626 (Anatomic Stage IIIA Breast Cancer AJCC v8)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03106077Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast CancerTreatment